Loading...
SANA logo

Sana Biotechnology, Inc.NasdaqGS:SANA Stock Report

Market Cap US$958.0m
Share Price
n/a
1Y1.9%
7D-8.4%
1D-1.3%
Portfolio Value
​
View

Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$958.0m

Sana Biotechnology (SANA) Stock Overview

A biotechnology company, focuses on utilizing engineered cells as medicines in the United States. More details

SANA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings have grown 7.2% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 8.9% per year for the next 3 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


SANA Community Fair Values

Create Narrative

See what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW445,219 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
445,219 investors already sharing narratives
View all narratives

Sana Biotechnology, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sana Biotechnology
Historical stock prices
Current Share PriceUS$3.16
52 Week HighUS$6.55
52 Week LowUS$2.61
Beta2.13
1 Month Change-10.99%
3 Month Change3.95%
1 Year Change1.94%
3 Year Change-28.02%
5 Year Change-86.67%
Change since IPO-91.00%

Recent News & Updates

Seeking Alpha • Jul 22

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Summary Sana Biotechnology is rated Sell due to excessive risk and overvaluation relative to its early-stage pipeline. Both lead assets, SC291 and SC451, are years from market and face low historical success rates, with SC291 only in Phase 1. The entire pipeline depends on the unproven Hypoimmune (HIP) platform; failure in early trials could invalidate the company. With $128.9M in cash and high burn, heavy dilution is likely for SANA, making the current $3.14 share price unjustified versus a $0.53 risk-adjusted fair value. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jul 22

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

Summary Sana Biotechnology is rated Sell due to excessive risk and overvaluation relative to its early-stage pipeline. Both lead assets, SC291 and SC451, are years from market and face low historical success rates, with SC291 only in Phase 1. The entire pipeline depends on the unproven Hypoimmune (HIP) platform; failure in early trials could invalidate the company. With $128.9M in cash and high burn, heavy dilution is likely for SANA, making the current $3.14 share price unjustified versus a $0.53 risk-adjusted fair value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Summary SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient. SANA also has ongoing Phase 1 trials for SC291 and SC262, with topline data expected in 2025. However, SANA does have high cash burn and dilution risks, which is why I just rate it a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Summary Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense. I rate SANA stock as a “Buy,” but advise caution as the stock may correct downward before long-term growth, given the early stage of clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Dec 04

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. The global Lupus drugs market is expected to reach $4.2 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Nov 19

Sana Biotechnology: The Story Becomes Murkier

Summary Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future. An updated analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Nov 01

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jul 14

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Summary Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively. Read the full article on Seeking Alpha
Analysis Article • Jul 12

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 17

Sana Biotechnology: Now In Overbought Territory

Summary Sana Biotechnology's shares have risen some 60% since a secondary offering in February, driven by positive early clinical and research results. The company is focused on developing engineered cells to treat diseases, using a hypoimmune technology platform to create cells that evade immune detection. Sana has three clinical programs in Phase 1 trials, with promising results seen in the treatment of B-cell cancer and type I diabetes. A full analysis around Sana Biotechnology follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Summary Sana Biotechnology's novel T1D treatment, not requiring immunosuppression, shows encouraging results in a non-human primate study. Sana displays improved Q3 financials with a current ratio of 4.03, but faces high cash burn and potential funding needs. Investment Stance: Shift from "Sell" to "Hold" based on Sana's financial management and R&D progress, with a watchful eye for further clinical and financial developments. Read the full article on Seeking Alpha
Analysis Article • Dec 30

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Sep 14

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 26

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 19

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 03

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jun 27

Sana Biotechnology A Buy For Potential Cancer Therapies

Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology. Clinical trials could begin in 2023, following INDs in 2022.
Analysis Article • May 16

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

SANAUS BiotechsUS Market
7D-8.4%-3.9%-1.5%
1Y1.9%40.0%13.3%

Return vs Industry: SANA underperformed the US Biotechs industry which returned 40% over the past year.

Return vs Market: SANA underperformed the US Market which returned 13.3% over the past year.

Price Volatility

Is SANA's price volatile compared to industry and market?
SANA volatility
SANA Average Weekly Movement10.1%
Biotechs Industry Average Movement9.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: SANA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SANA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018142Steve Harrwww.sana.com

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.

Sana Biotechnology, Inc. Fundamentals Summary

How do Sana Biotechnology's earnings and revenue compare to its market cap?
SANA fundamental statistics
Market capUS$957.95m
Earnings (TTM)-US$211.82m
Revenue (TTM)n/a
0.0x
P/S Ratio
-4.5x
P/E Ratio

Is SANA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SANA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$211.82m
Earnings-US$211.82m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SANA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 21:53
End of Day Share Price 2026/09/15 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sana Biotechnology, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Samantha Lynn SemenkowCitigroup Inc
Reni BenjaminCitizens JMP Securities, LLC